Business Context and Reporting Period
Company: Syndax Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 9, 2021
Reporting Period: Specific event date (December 9, 2021)
This filing reports the closing of a registered direct offering and the execution of a letter agreement related to a collaboration with Incyte Corporation.
Key Financial Metrics
Capital Raise:
- Shares Issued: 1,421,523 shares of common stock
- Aggregate Purchase Price: $35 million
- Price Per Share: $24.62
- Net Proceeds: Approximately $34.9 million (after estimated expenses)
Other Financial Data:
- Revenue/Profit/Cash Flow: The filing text does not provide a clear value for operating revenue, net income, or operating cash flow for this period.
- Debt/Liquidity: The filing text does not provide a clear value for total debt or current liquidity ratios, though the offering increased cash on hand by approximately $34.9 million.
Material Changes and Events
Closing of Stock Purchase Agreement:
- The Company closed the Offering with Incyte Corporation on December 9, 2021, as previously announced on September 24, 2021.
- No underwriter or placement agent participated in the Offering.
Collaboration Agreement Update:
- Entered into a letter agreement with Incyte regarding potential government intervention (FTC or DOJ Antitrust Division).
- Termination Right: Incyte may terminate the Collaboration Agreement through September 2022 if a formal antitrust request is received prior to March 23, 2022.
- Settlement Mechanism: If terminated, Syndax must refund the $117 million upfront license fee and other payments. Incyte must sell its shares and remit any gain to Syndax, or Syndax must repay Incyte for any loss.
- Status: No formal antitrust requests have been received to date.
Guidance, Outlook, and Risks
Updated Risk Factors:
- The Company filed a prospectus supplement updating risk factors, specifically regarding the Collaboration Agreement and potential regulatory intervention.
- These updates supplement disclosures in the Form 10-Q for the quarter ended September 30, 2021.
Management Commentary:
- The filing confirms the successful closing of the equity investment and the establishment of a mechanism to handle potential antitrust-related termination scenarios.
Investor Verification Checklist
- Verify the final net proceeds of $34.9 million in the next quarterly financial report.
- Monitor for any formal requests from the FTC or DOJ Antitrust Division before March 23, 2022, which could trigger the termination right.
- Review the full text of the letter agreement (to be filed in the 2021 Form 10-K) for detailed terms of the gain/loss settlement mechanism.
- Confirm the updated risk factors in the prospectus supplement (Exhibit 99.1) for specific regulatory language.